Pipeline

Advanced medicines that demonstrate both strong clinical performance and benefits to patients.

Pipeline
90
+
compounds, devices or indications in development individually or under collaboration or license agreement
investment
$7.8
b
R&D investment in 2023
Commitment
50
+
programs are in mid and late-stage development
Novel
80
%
of compounds in clinical development with a novel mechanism of action

Pipeline

Updated November 15, 2024

Sort By 
Focus Area
Molecule/Asset Phase
Molecule/Asset Type
Device Asset Phase
Device Asset Type
ABBV-319
Biologic C19 ∕ Steriod ADC Pharmaceutical Oncology
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Hematologic Tumors
N ∕ A
N ∕ A phase1
phase1
Lutikizumab
Biologic Immunology Pharmaceutical IL-1a ∕ 1b
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Hidradenitis Suppurativa
N ∕ A
N ∕ A phase3
phase3
Ulcerative Colitis
N ∕ A
N ∕ A phase2
phase2
ABBV-706
SEZ6 + Topo-1 ADC Biologic Pharmaceutical Oncology
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Small Cell Lung Cancer
N ∕ A
N ∕ A phase1
phase1
ABBV-181 (budigalimab)
Biologic Pharmaceutical anti-PD1 Oncology
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Solid Tumors
N ∕ A
N ∕ A phase2
phase2
ABBV-CLS-579
Small Molecule Pharmaceutical Oncology PTPN2 ∕ N1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
ABBV-CLS-484
Small Molecule Pharmaceutical Oncology PTPN2 ∕ N1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
IMGN-151
Biologic FR-alpha + DM21 maytansinoid Pharmaceutical Oncology
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Ovarian Cancer
N ∕ A
N ∕ A phase1
phase1
Endometrial Cancer
N ∕ A
N ∕ A phase1
phase1
ABBV-969
Biologic PSMA ∕ STEAP1 ADC Pharmaceutical Oncology
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
mCRPC
N ∕ A
N ∕ A phase1
phase1
Pivekimab Sunirine (PVEK)
Biologic Pharmaceutical Oncology CD123 + indolinobenzodiazepine DNA-targeting payload
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
BPDCN
N ∕ A
N ∕ A phase2
phase2
Acute Myeloid Leukemia
N ∕ A
N ∕ A phase2
phase2
ABBV-787
N ∕ A Pharmaceutical Oncology N ∕ A
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Acute Myeloid Leukemia
N ∕ A
N ∕ A phase1
phase1
ABBV-303
Biologic ∕ Multi-specific Antibody c-Met Pharmaceutical Oncology
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
ABBV-525
Small Molecule Pharmaceutical MALT1 Oncology
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Hematologic Tumors
N ∕ A
N ∕ A phase1
phase1
ABBV-453
Small Molecule Pharmaceutical Oncology Bcl-2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Relapsed ∕ Refractory Multiple Myeloma
N ∕ A
N ∕ A phase1
phase1
Armour Thyroid
Large Molecule Pharmaceutical T3T4 Other Specialties
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Hypothyroidism
N ∕ A
N ∕ A phase3
phase3
Aztreonam / Avibactam
Small Molecule Pharmaceutical PBP3 Other Specialties
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Complicated Gram-negative Infections
N ∕ A
N ∕ A submitted
submitted
ALPN-101
Biologic Dual CD28-ICOS Antagonist Immunology Pharmaceutical Partner Asset
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Systemic Lupus Erythematosus (SLE)
Global
Global phase2
phase2
ABBV-552
Small Molecule Pharmaceutical Neuroscience SV2A
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Alzheimer's Disease
N ∕ A
N ∕ A phase2
phase2
AL002
TREM 2 Biologic Pharmaceutical Neuroscience Partner Asset
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Alzheimer's Disease
N ∕ A
N ∕ A phase2
phase2
TTX-030
Biologic Pharmaceutical Oncology CD39 Partner Asset
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Advanced Pancreatic Cancer
N ∕ A
N ∕ A phase2
phase2
AGN-193408
Intracameral Implant Pharmaceutical Eye Care PGF2 alpha receptor
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Open Angle Glaucoma
N ∕ A
N ∕ A phase2
phase2
Ocular Hypertension
N ∕ A
N ∕ A phase2
phase2
ABBV-668
Immunology RIPK1 Small Molecule Pharmaceutical
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Ulcerative Colitis
N ∕ A
N ∕ A phase2
phase2
CUG-252
IL-2 Mutein Biologic Immunology Pharmaceutical Partner Asset
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Systemic Lupus Erythematosus (SLE)
N ∕ A
N ∕ A phase1
phase1
CLF065
GLP-2 agonist Biologic Immunology Pharmaceutical Partner Asset
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
IBD
N ∕ A
N ∕ A phase1
phase1
ABBV-RGX-314
Biologic Pharmaceutical Eye Care Partner Asset VEGF
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
wet AMD (subretinal)
N ∕ A
N ∕ A phase3
phase3
wet AMD (suprachoroidal)
N ∕ A
N ∕ A phase2
phase2
Diabetic Retinopathy (suprachoroidal)
N ∕ A
N ∕ A phase2
phase2
ABBV-101
BTK Small Molecule Pharmaceutical Oncology
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Hematologic Tumors
N ∕ A
N ∕ A phase1
phase1
BoNTE
Large Molecule Pharmaceutical SNARE Proteins Aesthetics
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Glabellar Lines
N ∕ A
N ∕ A phase3
phase3
OpSCF
Biologic Immunology Pharmaceutical Partner Asset SCF248
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Atopic Dermatitis
N ∕ A
N ∕ A phase2
phase2
Epcoritamab
Biologic DuoBody-CD3xCD20 Pharmaceutical Oncology Partner Asset
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Relapsed ∕ Refractory Diffuse Large B-cell Lymphoma
US , EU
US , EU approved
approved
Relapsed ∕ Refractory Follicular Lymphoma
N ∕ A
N ∕ A approved
approved
First Line Follicular Lymphoma
N ∕ A
N ∕ A phase3
phase3
First Line Large B-cell Lymphoma
US , EU
US , EU phase3
phase3
B-cell Non-Hodgkin lymphoma
N ∕ A
N ∕ A phase2
phase2
Relapsed ∕ Refractory Chronic Lymphocytic Leukemia
N ∕ A
N ∕ A phase1
phase1
Richter's Syndrome
N ∕ A
N ∕ A phase1
phase1
Elezanumab (ABT-555)
Biologic RGMa Pharmaceutical Neuroscience
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Spinal Cord Injury
N ∕ A
N ∕ A phase2
phase2
Acute Ischemic Stroke
N ∕ A
N ∕ A phase2
phase2
ABBV-932
Small Molecule Pharmaceutical DRD2 ∕ DRD3 Modulator Neuroscience Partner Asset
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Bipolar Depression
N ∕ A
N ∕ A phase1
phase1
ABBV-1882
anti-PD1 and anti-a4b7 mAb Biologic Pharmaceutical Other Specialties
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
HIV
N ∕ A
N ∕ A phase2
phase2
ABBV-1088
PINK1 Small Molecule Pharmaceutical Neuroscience
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Parkinson's Disease
N ∕ A
N ∕ A phase1
phase1
ABBV-113
Immunology Small Molecule Pharmaceutical NLRX1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Ulcerative Colitis
N ∕ A
N ∕ A phase2
phase2
ABBV-8736
Biologic Immunology Pharmaceutical TREM1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
IBD
N ∕ A
N ∕ A phase1
phase1
Emraclidine
M4 PAM Small Molecule Pharmaceutical Neuroscience
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Schizophrenia
N ∕ A
N ∕ A phase2
phase2
Alzheimer's Disease Psychosis
N ∕ A
N ∕ A phase1
phase1
Tavapadon
Small Molecule D1 ∕ D5 Partial Agonist Pharmaceutical Neuroscience
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Parkinson's Disease
N ∕ A
N ∕ A phase3
phase3
Razpipadon (CVL-871)
Small Molecule D1 ∕ D5 Partial Agonist Pharmaceutical Neuroscience
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Dementia-related Apathy
N ∕ A
N ∕ A phase2
phase2
Icalcaprant (CVL-354)
Small Molecule Pharmaceutical Neuroscience KOR antagonist
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Major Depressive Disorder
N ∕ A
N ∕ A phase1
phase1
SKYRIZI + ABBV-382
Biologic Immunology IL-23 + anti-a4b7 mAb Pharmaceutical
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Crohn's Disease
N ∕ A
N ∕ A phase2
phase2
SKYRIZI + Lutikizumab
Biologic Immunology Pharmaceutical IL-23 + IL-1a ∕ 1b
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Crohn's Disease
N ∕ A
N ∕ A phase2
phase2
SKYRIZI
Biologic Immunology IL-23 Pharmaceutical
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Crohn's Disease
US , EU
US , EU approved
approved
Psoriasis
US , EU
US , EU approved
approved
Psoriatic Arthritis
US , EU
US , EU approved
approved
Ulcerative Colitis
US , EU
US , EU approved
approved
Livmoniplimab (ABBV-151) + Budigalimab (ABBV-181)
Biologic GARP-TGF-β1 Pharmaceutical Oncology Partner Asset
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Liver
N ∕ A
N ∕ A phase2
phase2
Solid Tumors
N ∕ A
N ∕ A phase2
phase2
Non-Small Cell Lung Cancer
N ∕ A
N ∕ A phase2
phase2
Etentamig (ABBV-383)
CD3-BCMA Biologic Pharmaceutical Oncology
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Multiple Myeloma
N ∕ A
N ∕ A phase3
phase3
Immunoglobulin Light Chain (AL) Amyloidosis
N ∕ A
N ∕ A phase1
phase1
Teliso-V (ABBV-399)
Biologic c-Met Pharmaceutical Oncology
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Non-Small Cell Lung Cancer
N ∕ A
N ∕ A submitted
submitted
Temab-A (ABBV-400)
Biologic cMET + Topo-1 ADC Pharmaceutical Oncology
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Colorectal Cancer
N ∕ A
N ∕ A phase2
phase2
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
Fosigotifator (ABBV-CLS-7262)
eIF2B Small Molecule Pharmaceutical Neuroscience
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Amyotrophic Lateral Sclerosis (ALS)
N ∕ A
N ∕ A phase2
phase2
Vanishing White Matter disease (VWM)
N ∕ A
N ∕ A phase1
phase1
VENCLEXTA
Small Molecule Pharmaceutical Oncology Bcl-2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Acute Myeloid Leukemia
US , EU
US , EU approved
approved
Acute Myeloid Leukemia post transplant
N ∕ A
N ∕ A phase3
phase3
Chronic Lymphocytic Leukemia with 17p deletion
US , EU
US , EU approved
approved
First-line Chronic Lymphocytic Leukemia
US , EU
US , EU approved
approved
Myelodysplastic Syndrome
US , EU
US , EU phase3
phase3
Relapsed ∕ Refractory Chronic Lymphocytic Leukemia
US , EU
US , EU approved
approved
ABBV-514
Biologic Pharmaceutical Oncology CCR8
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
VYALEV
Dopamine Receptor Small Molecule Pharmaceutical Neuroscience Combination
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Parkinson's Disease
US , JA , EU
US , JA , EU approved
approved
Darigabat
Small Molecule Pharmaceutical Neuroscience GABA-A PAM
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Panic Disorder
N ∕ A
N ∕ A phase2
phase2
BOTOX
Large Molecule Pharmaceutical Neuroscience SNARE Proteins
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Episodic Migraine Prophylaxis
N ∕ A
N ∕ A phase3
phase3
Essential Tremor
N ∕ A
N ∕ A phase2
phase2
BOTOX
Large Molecule Pharmaceutical SNARE Proteins Other Specialties
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
IC BPS
N ∕ A
N ∕ A phase2
phase2
BOTOX
Large Molecule Pharmaceutical SNARE Proteins Aesthetics
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Platysma Prominence
US
US approved
approved
Masseter Prominence
CN N ∕ A
CN approved
N ∕ A phase3
approved
phase3
RINVOQ
Immunology Small Molecule JAK1 Pharmaceutical
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Alopecia Areata
N ∕ A
N ∕ A phase3
phase3
Ankylosing Spondylitis
US , EU
US , EU approved
approved
Atopic Dermatitis
US , EU
US , EU approved
approved
Axial SpA
US , EU
US , EU approved
approved
Crohn's Disease
US , EU
US , EU approved
approved
Giant Cell Arteritis
US , EU
US , EU submitted
submitted
Hidradenitis Suppurativa
N ∕ A
N ∕ A phase3
phase3
Psoriatic Arthritis
US , EU
US , EU approved
approved
Rheumatoid Arthritis
US , EU
US , EU approved
approved
Systemic Lupus Erythematosus (SLE)
N ∕ A
N ∕ A phase3
phase3
Takayasu Arteritis
JA
JA phase3
phase3
Ulcerative Colitis
US , EU
US , EU approved
approved
Vitiligo
N ∕ A
N ∕ A phase3
phase3
ELAHERE
FR-alpha + DM4 maytansinoid Biologic Pharmaceutical Oncology
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Platinum-Resistant Ovarian Cancer
N ∕ A
N ∕ A approved
approved
Platinum-Sensitive Ovarian Cancer
N ∕ A
N ∕ A phase3
phase3
Tropoelastin
Facial Aesthetics Device Skin Deformities Aesthetics
Potential Indication
Region
Feasibility Development Confirmation Status
Status
Atrophic Scars
N A
N A confirmation
confirmation
Resonic
Body Contouring Device Cellulite Aesthetics
Potential Indication
Region
Feasibility Development Confirmation Status
Status
Cellulite
N A
N A development
development
Next Generation Collagen Filler
Facial Aesthetics Device Facial Contouring Aesthetics
Potential Indication
Region
Feasibility Development Confirmation Status
Status
Facial Volume
N A
N A confirmation
confirmation
JUVEDERM VOLUMA XC
Facial Aesthetics Device Aesthetics Combination Age-Related Volume Loss
Potential Indication
Region
Feasibility Development Confirmation Status
Status
Temple Augmentation
US
US approved
approved
JUVEDERM VOLITE XC
Facial Aesthetics Device Skin Deformities Aesthetics Combination
Potential Indication
Region
Feasibility Development Confirmation Status
Status
Fine Line Reduction
US , EU , JA
US , EU , JA approved
approved
Neck Line Reduction
N A
N A confirmation
confirmation
HArmonyCa
Facial Aesthetics Device Facial Contouring Aesthetics Combination
Potential Indication
Region
Feasibility Development Confirmation Status
Status
Facial Volume
EU N A
EU approved
N A development
approved
development
JUVEDERM VOLBELLA XC
Facial Aesthetics Device Aesthetics Combination Infraorbital Hollowing
Potential Indication
Region
Feasibility Development Confirmation Status
Status
Infraorbital Hollowing
US
US approved
approved
JUVEDERM VOLUX XC
Facial Aesthetics Device Jawline Definition Aesthetics Combination
Potential Indication
Region
Feasibility Development Confirmation Status
Status
Jawline Definition
US
US approved
approved
No Results Found Change your filter or search criteria.
Popular pages
External links

Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.

Copyright © 2024 AbbVie Inc. North Chicago, Illinois, U.S.A.